VSV-IFNbetaTYRP1 / National Cancer Institute - LARVOL DELTA

A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses. (PubMed, Front Immunol) - "Our study found that VSV-IFNβ -TYRP1 can be safely administered via intratumoral (IT) and IV routes in a previously treated population of patients with MUM. Although there were no clear objective radiographic responses to VSV-IFNβ-TYRP1, dose-dependent immunogenicity to TYRP1 and other melanoma antigens was seen."

Journal • Oncolytic virus • P1 data • Eye Cancer • Melanoma • Oncology • Solid Tumor • Uveal Melanoma • IFNB1 • IFNG • Tyrosinase • TYRP1

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Mayo Clinic | Trial completion date: Apr 2024 ➔ Jan 2027 | Trial primary completion date: Apr 2024 ➔ Jan 2027

Metastases • Trial completion date • Trial primary completion date • Choroidal Melanomas • Cutaneous Melanoma • Eye Cancer • Melanoma • Mucosal Melanoma • Ocular Melanoma • Oncology • Uveal Melanoma • BRAF

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Mayo Clinic | Trial completion date: Apr 2023 ➔ Apr 2024 | Trial primary completion date: Apr 2023 ➔ Apr 2024

Metastases • Trial completion date • Trial primary completion date • Choroidal Melanomas • Cutaneous Melanoma • Eye Cancer • Melanoma • Mucosal Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma • BRAF

Phase I trial of vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 (VSV-IFNb-TYRP1) in metastatic ocular melanoma (AACR 2023) - "While OV response alone is not sufficient for clinical benefit, the evidence of epitope spreading is encouraging. Future studies of VSV-IFNb-TYRP1 will evaluate combinations with other therapies."

Metastases • P1 data • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma • IFNB1 • Tyrosinase • TYRP1

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Mayo Clinic | Suspended ➔ Active, not recruiting | N=72 ➔ 12

Enrollment change • Enrollment closed • Choroidal Melanomas • Cutaneous Melanoma • Eye Cancer • Melanoma • Mucosal Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma • BRAF

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma (clinicaltrials.gov) - P1 | N=72 | Suspended | Sponsor: Mayo Clinic | Trial completion date: Mar 2022 ➔ Apr 2023 | Recruiting ➔ Suspended | Trial primary completion date: Mar 2022 ➔ Apr 2023

Trial completion date • Trial primary completion date • Trial suspension • Choroidal Melanomas • Cutaneous Melanoma • Eye Cancer • Melanoma • Mucosal Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma • BRAF